Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.63 |
| ▸ | NOS1 | P29475 | 2/20 | 0.63 |
| ▸ | NOS2 | P35228 | 2/20 | 0.63 |
| ▸ | FNTA | P49354 | 14/20 | 0.36 |
| ▸ | FNTB | P49356 | 14/20 | 0.36 |
| ▸ | PGGT1B | P53609 | 12/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5966508 | 0.83 | NOS3 (0.56) | NOS3NOS1NOS2FNTAFNTB | |
| SCHEMBL5966642 | 0.83 | NOS3 (0.56) | NOS3NOS1NOS2FNTAFNTB | |
| SCHEMBL5271958 | 0.78 | NOS1 (1.00) | NOS3NOS1NOS2 | |
| SCHEMBL2237559 | 0.76 | NOS3 (0.55) | NOS3NOS1NOS2 | |
| SCHEMBL5966652 | 0.76 | NOS3 (0.55) | NOS3NOS1NOS2 | |
| SCHEMBL3671155 | 0.76 | NOS1 (0.61) | NOS3NOS1NOS2 | |
| SCHEMBL5966506 | 0.74 | NOS3 (0.50) | NOS3NOS1NOS2 | |
| Phosphoric Acid SCHEMBL7074988 | 0.74 | NOS1 (0.89) | NOS3NOS1NOS2 | |
| SCHEMBL30531616 | 0.74 | FNTA (0.49) | FNTAFNTBPGGT1B | |
| SCHEMBL4302043 | 0.74 | FNTA (0.49) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024323-B1 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE | GICARE PHARMA INC (CA) | 2013-03-27 | — | — | EP | disclosed |
| US-20110144188-A1 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE | ANTIBE THERAPEUTICS INC. (CA) | 2011-06-16 | — | — | US | disclosed |
| US-7666907-B2 | Salts of trimebutine and N-desmethyl trimebutine | ANTIBE THERAPEUTICS INC. (CA) | 2010-02-23 | — | — | US | disclosed |
| EP-2024323-A1 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE | Antibe Therapeutics Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007140611-A1 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE | ANTIBE THERAPEUTICS INC. (CA) | 2007-12-13 | — | — | WO | disclosed |
| US-20070275905-A1 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE | ANTIBE THERAPEUTICS INC. (CA) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144188-A1 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE | SI, VIP, TRIM59 | NOS3 1318/4885NOS1 1259/4885NOS2 984/4885 |
| US-20070275905-A1 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE | SI, VIP, TRIM59 | NOS3 1318/4885NOS1 1259/4885NOS2 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.